Introduction

The Federal Trade Commission, joined by seven states, has asked a federal court to enforce a lifetime ban against Martin Shkreli, the figure known as Pharma Bro for dramatically raising drug prices in 2015.

What Happened

Federal prosecutors allege Shkreli has traded at least 60 pharmaceutical stocks since his release from prison in 2022, often broadcasting his trades and market opinions via livestreams and social media. A coalition of state attorneys general has requested that a judge hold him in contempt and order him to forfeit all trading profits from pharma holdings.

Why This Matters

Shkreli was previously convicted of fraud and banned from the pharmaceutical industry for life after attempting to block generic competition for Daraprim. His alleged continued involvement in stock trading and public investment advice raises concerns about market manipulation and investor protection.

Key Takeaways

  • The FTC and state coalition are seeking financial penalties, including a fine equal to Shkreli's trading profits from pharmaceutical stocks.
  • If found in contempt, Shkreli could face additional financial penalties and potential incarceration.
  • This case marks a second federal effort to hold Shkreli accountable, following a 2023 contempt motion over unpaid fines and alleged cooperation failures.
  • A prior court order permanently barred Shkreli from the drug industry after he was found to have interfered with generic drug competition.

Conclusion

The outcome of this federal case will determine whether Shkreli faces significant legal consequences for allegedly circumventing a lifetime industry ban, setting a potential precedent for enforcement against former executives who remain active in regulated sectors.